Skip to main content
Top
Published in: Journal of Cardiothoracic Surgery 1/2024

Open Access 01-12-2024 | Cardiomyopathy | Research

Transapical intramyocardial septal microwave ablation in treatment of hypertrophic obstructive cardiomyopathy: 12-month outcomes of a swine model

Authors: Mi Zhou, Zhaolong Li, Yun Liu, Yuehua Fang, Le Qin, Wenjie Yang, Fuhua Yan, Qiang Zhao

Published in: Journal of Cardiothoracic Surgery | Issue 1/2024

Login to get access

Abstract

Background

To date, the extended Morrow procedure is considered the gold standard treatment for patients with obstructive hypertrophic cardiomyopathy who experience severe symptoms and are unresponsive to medication treatment. We therefore aimed to perform transapical intramyocardial septal microwave ablation to reduce the thickness of the interventricular septum myocardium in a minimally invasive method.

Methods

Fourteen swine were divided to form either a microwave ablation group (n = 7) or a sham group (n = 7). In the microwave ablation group, a transapical microwave antenna was inserted into the septum to ablate each myocardial segment at 40 W for 1 min, while in the sham group, the same operation was performed but without power output. We used echocardiography, electrocardiogram, during the operation. And added computerized tomography, cardiac nuclear magnetic resonance during follow-up.

Results

Segment hypokinesis was observed in all swine immediately following ablation. Compared with the sham group, the thickness of ablated segments in the ablation group decreased significantly 1 month post-operation (ablation group, 5.53 ± 1.00 mm vs. 8.03 ± 1.15 mm, respectively, P < 0.01; sham group, 8.40 ± 0.94 mm vs. 8.21 ± 1.09 mm, respectively, P = 0.081), and the outcome was still observed 1 year post-operation (ablation group, 3.36 ± 0.85 mm vs. 8.03 ± 1.15 mm, respectively, P < 0.01). No perforation of the septum was observed during the procedure or follow-up, and no heart failure or sudden cardiac death occurred during postoperative feeding.

Conclusions

Transapical intramyocardial septal microwave ablation can effectively and safely produce a large region of necrosis. This technique can potentially mimic surgical myectomy while avoiding cardiopulmonary bypass and median sternotomy in high-risk hypertrophic obstructive cardiomyopathy patients.
Appendix
Available only for authorised users
Literature
1.
go back to reference Maron BJ, Rowin EJ, Maron MS. Global burden of hypertrophic cardiomyopathy. JACC Heart Fail. 2018;6:376–8.CrossRefPubMed Maron BJ, Rowin EJ, Maron MS. Global burden of hypertrophic cardiomyopathy. JACC Heart Fail. 2018;6:376–8.CrossRefPubMed
2.
go back to reference Mestres CA, Bartel T, Sorgente A, Müller S, Cruner C, Dearani J, Quintana E. Hypertrophic obstructive cardiomyopathy: what, when, why, for whom? Eur J Cardiothorac Surg. 2018;53:700–7.CrossRefPubMed Mestres CA, Bartel T, Sorgente A, Müller S, Cruner C, Dearani J, Quintana E. Hypertrophic obstructive cardiomyopathy: what, when, why, for whom? Eur J Cardiothorac Surg. 2018;53:700–7.CrossRefPubMed
3.
go back to reference Alashi A, Smedira NG, Hodges K, et al. Outcomes in guideline-based class I indication versus earlier referral for surgical myectomy in hypertrophic obstructive cardiomyopathy. J Am Heart Assoc. 2021;10:e016210.CrossRefPubMed Alashi A, Smedira NG, Hodges K, et al. Outcomes in guideline-based class I indication versus earlier referral for surgical myectomy in hypertrophic obstructive cardiomyopathy. J Am Heart Assoc. 2021;10:e016210.CrossRefPubMed
4.
go back to reference Cui H, Schaff HV, Wang S, et al. Survival following alcohol septal ablation or septal myectomy for patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2022;79:1647–55.CrossRefPubMed Cui H, Schaff HV, Wang S, et al. Survival following alcohol septal ablation or septal myectomy for patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2022;79:1647–55.CrossRefPubMed
5.
go back to reference Wei LM, Thibault DP, Rankin JS, et al. Contemporary surgical management of hypertrophic cardiomyopathy in the United States. Ann Thorac Surg. 2019;107:460–6.CrossRefPubMed Wei LM, Thibault DP, Rankin JS, et al. Contemporary surgical management of hypertrophic cardiomyopathy in the United States. Ann Thorac Surg. 2019;107:460–6.CrossRefPubMed
6.
go back to reference Lu Y, Nan Q, Du J, et al. Experimental study on thermal field in the vicinity of arterial bifurcation in microwave ablation therapy. Int J Hyperth. 2010;26(4):316–26.CrossRef Lu Y, Nan Q, Du J, et al. Experimental study on thermal field in the vicinity of arterial bifurcation in microwave ablation therapy. Int J Hyperth. 2010;26(4):316–26.CrossRef
7.
go back to reference Nan Q, Zheng W, Fan Z. Yi Zeng. Analysis to a critical state of thermal field in microwave ablation of liver cancer influenced by large vessels. Int J Hyperth. 2010;26(1):34–8.CrossRef Nan Q, Zheng W, Fan Z. Yi Zeng. Analysis to a critical state of thermal field in microwave ablation of liver cancer influenced by large vessels. Int J Hyperth. 2010;26(1):34–8.CrossRef
8.
go back to reference Tuohy CV, Kaul S, Song HK, Nazer B, Heitner SB. Hypertrophic cardiomyopathy: the future of treatment. Eur J Heart Fail. 2020;22:228–40.CrossRefPubMed Tuohy CV, Kaul S, Song HK, Nazer B, Heitner SB. Hypertrophic cardiomyopathy: the future of treatment. Eur J Heart Fail. 2020;22:228–40.CrossRefPubMed
9.
go back to reference Hodges K, Rivas CG, Aguilera J, et al. Surgical management of left ventricular outflow tract obstruction in a specialized hypertrophic obstructive cardiomyopathy center. J Thorac Cardiovasc Surg. 2019;157:2289–99.CrossRefPubMed Hodges K, Rivas CG, Aguilera J, et al. Surgical management of left ventricular outflow tract obstruction in a specialized hypertrophic obstructive cardiomyopathy center. J Thorac Cardiovasc Surg. 2019;157:2289–99.CrossRefPubMed
10.
go back to reference Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. J Am Coll Cardiol. 2020;76:3022–55.CrossRefPubMed Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. J Am Coll Cardiol. 2020;76:3022–55.CrossRefPubMed
11.
go back to reference Jensen MK, Faber L, Liebregts M, et al. Effect of impaired cardiac conduction after alcohol septal ablation on clinical outcomes: insights from the Euro-ASA registry. Eur Heart J Qual Care Clin Outcomes. 2019;5:252–8.CrossRefPubMed Jensen MK, Faber L, Liebregts M, et al. Effect of impaired cardiac conduction after alcohol septal ablation on clinical outcomes: insights from the Euro-ASA registry. Eur Heart J Qual Care Clin Outcomes. 2019;5:252–8.CrossRefPubMed
12.
go back to reference Vriesendorp PA, Van Mieghem NM, Vletter WB, Ten Cate FJ, de Jong PL, Schinkel AFL, Michels M. Microsphere embolisation as an alternative for alcohol in percutaneous transluminal septal myocardial ablation. Neth Heart J. 2013;21:245–8.CrossRefPubMedPubMedCentral Vriesendorp PA, Van Mieghem NM, Vletter WB, Ten Cate FJ, de Jong PL, Schinkel AFL, Michels M. Microsphere embolisation as an alternative for alcohol in percutaneous transluminal septal myocardial ablation. Neth Heart J. 2013;21:245–8.CrossRefPubMedPubMedCentral
13.
go back to reference Yang H, Yang Y, Xue Y, Luo S. Efficacy and safety of radiofrequency ablation for hypertrophic obstructive cardiomyopathy: a systematic review and meta-analysis. Clin Cardiol. 2020;43:450–8.CrossRefPubMedPubMedCentral Yang H, Yang Y, Xue Y, Luo S. Efficacy and safety of radiofrequency ablation for hypertrophic obstructive cardiomyopathy: a systematic review and meta-analysis. Clin Cardiol. 2020;43:450–8.CrossRefPubMedPubMedCentral
14.
go back to reference Liu L, Li J, Zuo L, et al. Percutaneous intramyocardial septal radiofrequency ablation for hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol. 2018;72:1898–909.CrossRefPubMed Liu L, Li J, Zuo L, et al. Percutaneous intramyocardial septal radiofrequency ablation for hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol. 2018;72:1898–909.CrossRefPubMed
17.
go back to reference Cui H, Schaff HV, Nishimura RA, et al. Conduction abnormalities and long-term mortality following septal myectomy in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2019;74:645–55.CrossRefPubMed Cui H, Schaff HV, Nishimura RA, et al. Conduction abnormalities and long-term mortality following septal myectomy in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2019;74:645–55.CrossRefPubMed
Metadata
Title
Transapical intramyocardial septal microwave ablation in treatment of hypertrophic obstructive cardiomyopathy: 12-month outcomes of a swine model
Authors
Mi Zhou
Zhaolong Li
Yun Liu
Yuehua Fang
Le Qin
Wenjie Yang
Fuhua Yan
Qiang Zhao
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Journal of Cardiothoracic Surgery / Issue 1/2024
Electronic ISSN: 1749-8090
DOI
https://doi.org/10.1186/s13019-024-02677-z

Other articles of this Issue 1/2024

Journal of Cardiothoracic Surgery 1/2024 Go to the issue